Onychomycosis Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 3.36 Billion |
| Market Size (2029) | USD 4.18 Billion |
| CAGR (2024 - 2029) | 4.46 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Onychomycosis Treatment Market Analysis
The Global Onychomycosis Treatment Market size is estimated at USD 3.36 billion in 2024, and is expected to reach USD 4.18 billion by 2029, growing at a CAGR of 4.46% during the forecast period (2024-2029).
Clinical examination, dermoscopy, and mycological examination were recommended for all patients with suspected onychomycosis prior to the COVID-19 pandemic. Non-urgent in-patient visits are being postponed as the COVID-19 pandemic spreads, and telemedicine may be used to handle some elements of onychomycosis diagnosis and treatment. Telemedicine can be used to assess individuals with suspected onychomycosis, although it's best for those who have already had their mycological confirmation. As a result, the COVID-19 pandemic is projected to cause a short-term interruption in the market. However, the revenue growth rate is predicted to recover during the forecast period, and the global onychomycosis market is expected to increase at a double-digit rate.
Onychomycosis traditionally referred to a non-dermatophytic infection of the nail but is now used as a general term to denote any fungal nail infection (tinea unguium specifically describes a dermatophytic invasion of the nail plate). Onychomycosis is of different types, such as superficial onychomycosis, distal and lateral subungual onychomycosis, proximal subungual onychomycosis, endonyx onychomycosis, and total dystrophic onychomycosis. Only around half of nail dystrophies are caused by a fungus; hence onychomycosis accounts for one-third of fungal skin infections.
The increasing geriatric population, rising prevalence of onychomycosis, diabetic population worldwide, and growing awareness about the potential threats of onychomycosis are the key driving factors in the onychomycosis treatment market. According to an article titled, 'High prevalence of mixed infections in global onychomycosis,' published in 2020, onychomycosis is estimated to occur at a prevalence of 10% worldwide, with the infecting organism most commonly being Trichophyton rubrum. In addition, according to World Health Organization's (WHO) data in 2021, by 2030, one out of every six persons on the globe will be aged 60 years or older. The number of people aged 60 years and more is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of adults aged 60 years and above will have doubled (2.1 billion).
Onychomycosis Treatment Market Trends
This section covers the major market trends shaping the Onychomycosis Treatment Market according to our research experts:
The Drugs Segment is Expected to Hold a Major Share in the Onychomycosis Treatment Market
Some of the drugs available for the treatment of onychomycosis are terbinafine, ciclopirox, Jublia, Fluconazole, Penlac, ciclodan, ketoconazole, Sporanox, Itraconazole, Kerydin, efinaconazole, griseofulvin, and so on. For onychomycosis treatment, drugs remain the first-line treatment choice and hold a major market share owing to a consistently high success rate.
Elewski and Charif's onychomycosis report states that approximately 40% of the elderly population have onychomycosis and a reduction in nail growth rate ranges from about 40% to 60% in persons aged above 65 years. Furthermore, onychomycosis affects approximately 2% to 26% of different populations globally. However, less than 30% of individuals infected with onychomycosis seek medical advice or treatment in developed countries.
The drugs segment holds a significant share in the onychomycosis treatment market. It is anticipated to show a similar trend over the forecast period due to the products' highly effective nature and easy availability. In July 2021, Lupin received approval to launch Tavaborole Topical Solution 5% in the US from the US Food and Drug Administration (FDA).
Due to the COVID-19 pandemic, the distribution of drugs was disrupted worldwide due to the supply chain disruptions and was expected to have an impact in 2020. However, in late 2020, 2021, and further years, the onychomycosis market was expected to recover and even show positive growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a major share in the global onychomycosis treatment market due to high drug costs, rising geriatric population, and increasing prevalence of onychomycosis and diabetic patient populations in this region. According to the Census Bureau's 2020 population estimates, more than 55 million Americans are aged 65 years or older, of which one-fourth live in one of three states, namely, California, Florida, and Texas. Seven other states, including Georgia, Illinois, Michigan, New York, account for roughly another quarter of the 65+ population.
The reasons for the age-related increase in onychomycosis include a variety of factors, like repeated nail trauma, poor peripheral circulation, diabetes, suboptimal immune function, longer exposure to pathogenic fungi, inactivity, or the inability to cut toenails or maintain good foot care. Various strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position.
In October 2020, US-headquartered Pfizer Inc. announced that it had begun clinical studies concerning onychomycosis. The first one involved a study determining whether the AN2690 topical solution is an effective treatment for onychomycosis of the toenail. The second one was an open-label study to evaluate the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in both children and adolescents.
On the other hand, the COVID-19 pandemic has resulted in decreased diagnosis and impacted the sales revenue of drugs and other treatment methods for onychomycosis as hospitals and primary care centers shifted their focus to COVID-19 patients.
Onychomycosis Treatment Industry Overview
The onychomycosis treatment market is fragmented and competitive and consists of several major players. Companies are focusing on developments, collaborations, and product launches to strengthen their market position. For instance, in April 2020, the US Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution used to treat onychomycosis in the toenail(s) in patients aged six years and above.
Some of the players currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.
Onychomycosis Treatment Market Leaders
-
Bausch Health Companies Inc (Valeant Pharmaceuticals Inc)
-
Galderma S.A.
-
Novartis AG
-
Pfizer, Inc
-
Moberg Pharma AB
*Disclaimer: Major Players sorted in no particular order
Onychomycosis Treatment Market News
In April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) had received tentative approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.
In February 2021, Lupin Limited received the US Food and Drug Administration's approval for its Tavaborole Topical Solution for onychomycosis.
Onychomycosis Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Onychomycosis Globally
- 4.2.2 Growing Awareness on the Potential Threats of Onychomycosis
-
4.3 Market Restraints
- 4.3.1 Side Effects Associated with Onychomycosis Treatment Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Treatment Type
- 5.1.1 Drugs
- 5.1.2 Laser Therapy
- 5.1.3 Photodynamic Therapy
-
5.2 By Type
- 5.2.1 Distal Subungual Onychomycosis
- 5.2.2 White Superficial Onychomycosis
- 5.2.3 Proximal Subungual Onychomycosis
- 5.2.4 Other Types
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- 6.1.2 Galderma SA
- 6.1.3 Novartis AG
- 6.1.4 Pfizer Inc.
- 6.1.5 Moberg Pharma AB
- 6.1.6 Johnson & Johnson
- 6.1.7 Bayer AG
- 6.1.8 Dr. Reddys Laboratories Ltd
- 6.1.9 Cipla Ltd
- 6.1.10 Lumenis Ltd
- 6.1.11 Medimetriks Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityOnychomycosis Treatment Industry Segmentation
As per the scope of the report, onychomycosis is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed, or plate. The onychomycosis treatment market is segmented by treatment type (drugs, laser therapy, and photodynamic therapy), type (distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis, and other types), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment Type | Drugs | |
| Laser Therapy | ||
| Photodynamic Therapy | ||
| By Type | Distal Subungual Onychomycosis | |
| White Superficial Onychomycosis | ||
| Proximal Subungual Onychomycosis | ||
| Other Types | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Onychomycosis Treatment Market Research FAQs
How big is the Global Onychomycosis Treatment Market?
The Global Onychomycosis Treatment Market size is expected to reach USD 3.36 billion in 2024 and grow at a CAGR of 4.46% to reach USD 4.18 billion by 2029.
What is the current Global Onychomycosis Treatment Market size?
In 2024, the Global Onychomycosis Treatment Market size is expected to reach USD 3.36 billion.
Who are the key players in Global Onychomycosis Treatment Market?
Bausch Health Companies Inc (Valeant Pharmaceuticals Inc) , Galderma S.A., Novartis AG, Pfizer, Inc and Moberg Pharma AB are the major companies operating in the Global Onychomycosis Treatment Market.
Which is the fastest growing region in Global Onychomycosis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Onychomycosis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Onychomycosis Treatment Market.
What years does this Global Onychomycosis Treatment Market cover, and what was the market size in 2023?
In 2023, the Global Onychomycosis Treatment Market size was estimated at USD 3.22 billion. The report covers the Global Onychomycosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Onychomycosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Onychomycosis Treatment Industry Report
The Onychomycosis Treatment Market is segmented by treatment type, including drugs, laser therapy, and photodynamic therapy, as well as by type, such as distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis, and other types. The market is analyzed across various geographies, including North America, Europe, Asia-Pacific, the Middle-East and Africa, and South America. The market report provides a comprehensive industry analysis and market overview, offering insights into market trends, market growth, and market segmentation.
The industry report covers market data and market value, highlighting the industry size and market size. It includes market analysis and market research, with a focus on market share and market leaders. The industry outlook and market outlook are discussed, along with industry trends and market trends.
The report features a market forecast and market predictions, providing a detailed market review and industry information. It also includes a report example and report pdf for further reference. The industry research and research companies involved in the study provide valuable industry statistics and industry sales data.
Overall, this report delivers a thorough analysis of the onychomycosis treatment market, offering insights into market growth and the industry outlook. The market segmentation and market value are examined, providing a detailed understanding of the industry landscape. The report is an essential resource for understanding the current and future state of the onychomycosis treatment market.
